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Abstract
Contagious caprine pleuropneumonia has been assessed according to the criteria of the Animal Health
Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of
contagious caprine pleuropneumonia to be listed, Article 9 for the categorisation of contagious caprine
pleuropneumonia according to disease prevention and control rules as in Annex IV and Article 8 on the
list of animal species related to contagious caprine pleuropneumonia. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, contagious
caprine pleuropneumonia can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL. The disease would comply with the criteria as in Sections 4 and 5 of Annex IV
of the AHL, for the application of the disease prevention and control rules referred to in points (d) and
(e) of Article 9(1). The assessment here performed on compliance with the criteria as in Section 1 of
Annex IV referred to in point (a) of Article 9(1) is inconclusive. The animal species to be listed for
contagious caprine pleuropneumonia according to Article 8(3) criteria are goats and other species of
the family Bovidae as susceptible.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on contagious caprine pleuropneumonia
(CCPP) according to the criteria of the AHL articles as follows:
• Article 7: contagious caprine pleuropneumonia proﬁle and impacts
• Article 5: eligibility of contagious caprine pleuropneumonia to be listed
• Article 9: categorisation of contagious caprine pleuropneumonia according to disease prevention
and control rules as in Annex IV
• Article 8: list of animal species related to contagious caprine pleuropneumonia.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of CCPP according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Introduction and deﬁnition: CCPP is an infectious and contagious respiratory disease affecting goats
as well as some wild ruminant species which is caused by a wall-less bacteria (Mollicute), Mycoplasma
capricolum subsp. capripneumoniae (Mccp). It is characterised by a unilateral acute inﬂammation in
the lung and pleural cavity of susceptible animals leading to large quantities of infective droplets being
excreted when the animals are coughing.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Wild goat (Capra aegagrus), Nubian ibex (Capra ibex nubiana), Laristan mouﬂon (Ovis orientalis
laristanica), gerenuk (Litocranius walleri) (Arif et al., 2007)
Tibetan antelope (Pantholops hodgsonii) (Yu et al., 2013)
Arabian oryx (Oryx leucoryx) (Chaber et al., 2014)
Sand gazelles (Gazella marica) (Lignereux et al., 2017)
It is probable that other wild ruminant species could be affected by CCPP; however, susceptibility to
Mccp of wild species present in the Union is not known.
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Parameter 2 – Naturally susceptible domestic species (or family/orders)
Goats (Capra hircus)
Sheep may be affected, but it is not clear if Mccp was responsible for the observed lesions (B€olske
et al., 1995). Mycoplasma ovipneumoniae is regularly isolated from pneumonic lesions and it could play
a role in the development of the lesions, notably in sheep.
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Not known.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
None except goats.
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
It is unclear if wild ruminant species are acting as a reservoir or simply as dead-end hosts for CCPP.
The recent detection of CCPP in wildlife could result either from improved diagnostic techniques and
awareness or from increased contacts between goats and wildlife.
Parameter 6 – Domestic reservoir species (or family/orders)
Sheep may play the role of domestic reservoirs although there is no clear evidence on this. Similarly
to wildlife, sheep could be contaminated after being in contact with infected goats. Publications before
1980 are affected by the lack of knowledge on which mycoplasma species was causing CCPP. After
1980, Mccp was detected in sheep in Kenya (Litamoi et al., 1990), in Uganda (B€olske et al., 1995) and
in Ethiopia (Shiferaw et al., 2006). In a retrospective study in southern Tanzania in 2007, the
seroprevalence of CCPP was estimated at 52% for the goat population and 37% for the sheep
population (Mbyuzi et al., 2014). The isolation of Mccp and the presence of antibodies in sheep
indicate clearly that Mccp can multiply in sheep and induce an immunological response from the
infected animals. However, the long-term persistence of Mccp in sheep is yet to be proven.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/ Incidence
The prevalence and incidence may vary greatly according to the local epidemiological situation and
the type of diagnostic test used. In the regions where the disease is enzootic, serological surveys may
result in various prevalence rates according to the locations (Peyraud et al., 2014). For example, in the
Afar region in Ethiopia, 15% of the goats tested positive to the competitive enzyme-linked
immunosorbent assay (cELISA) method, which is highly speciﬁc. In the Narok region, all tested goat
ﬂocks were positive (convenience sampling as owners that suffered losses from CCPP were more likely
to bring their animals for vaccination) and individual prevalence ranged from 6% to 90%.
CCPP is quite common in Saudi Arabia, as more than 190 pleural ﬂuid samples could be retrieved
from 15 goat ﬂocks from which 55 Mccp isolates could be retrieved and identiﬁed by speciﬁc
polymerase chain reaction (PCR) (El-Deeb et al., 2017).
A very high seroprevalence was reported in Southern Tanzania in goats, from 35% (N = 434) to
52% (N = 447) (Mbyuzi et al., 2014). The same study reported also a high seroprevalence in sheep in
the same region (23% (N = 70) to 36% (N = 30)). If conﬁrmed, these ﬁgures may indicate that Mccp
may circulate in sheep.
In eastern Turkey, where the presence of CCPP has been acknowledged over the last 20 years, in a
ﬁeld study conducted in 2006–2007, CCPP was suspected in 24 herds and Mccp was isolated from
37.5% of goats in 10 of those different herds located in geographically distinct areas (Cetinkaya et al.,
2009). In Ethiopia, a meta-analysis conducted in 2015 reported that the pooled prevalence estimate
for CCPP for goat samples collected at abattoir was 39.2%, while that of samples collected at ﬁeld
level was 22.4% (Asmare et al., 2016). In Borana pastoral areas of Ethiopia, where outbreaks of CCPP
have been reported from almost all regions of the country, during June–September 2004, 217 goats
were examined in the abattoir for the presence of CCPP lesions with 21 (9.7%) showing pathological
lesions, whereas the prevalence rate for those aged 1–2 years was 13.3% (Gelagay et al., 2007).
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The data on CCPP prevalence are quite scarce because:
• Mccp is difﬁcult to isolate in laboratories with no speciﬁc skills regarding this pathogen.
• Goats are frequently infected by other mycoplasmas of the M. mycoides cluster and CCPP is
often confused with these infections or with peste des petits ruminants (PPR) which is the
most frequently found in many parts of the world. Therefore, PCR is often not performed
although this should be the routine procedure for CCPP identiﬁcation.
• The cELISA for CCPP has been marketed only recently by IDEXX and is not routinely used.
Parameter 2 – Case morbidity rate (% clinically diseased animals out of infected ones)
In experimental infections, the transmission of the disease by intubation or by contact is often very
successful, with about 100% of the goats showing symptoms (MacOwan and Minette, 1978; Harbi
et al., 1983).
In the case of an introduction into a fully na€ıve population, the morbidity can be high. This was the
case when CCPP was ﬁrstly introduced in South Africa (Hutcheon, 1881) from Turkey, and morbidity
reached more than 80%.
In Greece, CCPP was demonstrated between 1920 and 1930 (Stylianopoulos, 1933). Morbidity was
maximal (98%).
In Eritrea, morbidity reached 90% in two affected goat herds in 1997 (Houshaymi et al., 2002).
Thomas records morbidity values that range from 5% at lower altitudes to 30% and up to 56% or
68% at higher altitude (cold weather is thought to be a predisposing factor) (Thomas, 1873).
In eastern Turkey, CCPP was suspected in 24 herds, which comprised 1,122 animals, and within
these herds, 459 animals (41%) showed respiratory distress (Cetinkaya et al., 2009).
Mortality
Parameter 3 – Case fatality rate
In the case of acute outbreaks, the case fatality rate is very high when no antibiotics are
administered. In old observations, it is very often the crude mortality rate that is recorded (proportion
of dead animals out of the whole population) and it may be higher than 75% (Hutcheon, 1881).
In Greece, it varied from herd to herd from 60% to 94% (Stylianopoulos, 1933).
In Algeria, it varied from 50% to 75% (Thomas, 1873).
In Kenya, mortality rates reached more than 50% during natural outbreaks (Litamoi et al., 1989).
In the United Arab Emirates, the mortality in herds of Sand Gazelles affected by CCPP reached 70%
(Lignereux et al., 2017).
In Oman, nearly 600 outbreaks caused by CCPP were reported between 2008 and 2009 with
mortality rates of nearly 10% of 30,000 cases (Nicholas and Churchward, 2012). There are few reports
with only limited mortality. This was the case during an experimental infection in Kenya, where 50% of
the goats were infected (8/17), but no mortality was observed (Wesonga et al., 2004). All authors
agreed on the fact that mortality rates declined progressively in affected herds as time went by.
As there are a number of antibiotics that are efﬁcient to treat CCPP, it is to be expected that the
observed mortality/mortality rates in the ﬁeld, in developed countries, would be much lower.
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
CCPP is not zoonotic.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
There are no publications available on Mccp antimicrobial resistance. However, similarly to other
mycoplasmas, it is quite common to observe resistant variants to a number of antibiotics. For example,
mutations conferring resistance to erythromycin are observed with a probability of 107.5, a higher
value than for the closely related M. capricolum subsp. capricolum (Thiaucourt, 2017). Nevertheless,
animals are not treated in the European Union (EU) against Mccp infection; there would not be any
signiﬁcant danger to animal health as a consequence of possible development of drug resistance.
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3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
The duration of the infectious period has been estimated at about 19 days by an in silico model
(Lignereux et al., 2017). However, from a practical point of view, two phases of the disease should be
considered:
• The acute stage where excretion is maximum, and when the lungs are ﬁlled with exudate
containing very high concentrations of Mccp (109/mL). This stage is short and may last from 5
to 10 days until animals die (most frequent case in the absence of antibiotic treatment) or
recover.
• The recovery stage when affected animals may still shed Mccp until they are completely
recovered. However, there is no precise data on the duration of this stage.
The exact persistence of infectivity after the acute phase in surviving animals is not known.
Parameter 2 – Presence and duration of latent infection period
This parameter was estimated with an in silico model at 7 days (Lignereux et al., 2017).
Parameter 3 – Presence and duration of the pathogen in healthy carriers
There are very few data concerning this aspect. Mccp is able to survive in animals not showing any
clinical sign and some differences exist in breed susceptibility. In Tunisia, for example, CCPP was
clinically evident in alpine goats imported from France, while the local goats apparently were not
affected (Perreau, 1982). Similarly, CCPP was introduced from Turkey to South Africa with a shipment
of angora goats that were transported by boat. The travel lasted 7 weeks, and no symptoms were
observed during the transport (Hutcheon, 1881).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
While there is no experimental data published in support, it appears that Mccp is more fragile than
Mycoplasma mycoides subsp. mycoides (Mmm) (the agent of contagious bovine pleuropneumonia
(CBPP)) and does not survive in the environment.
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
To summarise the routes of transmission based on their importance:
• Direct contact is the main source of contamination/transmission (OIE, 2009)
• Some cases of distant spread have been speculated to occur by airborne transmission
(Lignereux et al., 2017)
• Vectors are not considered to play any role in the transmission of CCPP
• Fomites are not considered to play any role in the transmission of CCPP
• Animal products do not play any role in the transmission of CCPP
• Environmental contamination is considered negligible due to the fragility of mycoplasmas
This information is inferred from the knowledge gained with CBPP. The two diseases are very
similar except that Mccp is even more fragile than Mmm.
There are so few well-described outbreaks of CCPP that actual ﬁgures cannot be retrieved.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
None.
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Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
No published data exist for CCPP.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
R0 has been established at around 2.5 for gazelles in an environment that was very favourable to
transmission (high densities of animals held in pens) (Lignereux et al., 2017). Hence, the value for
goats in the ﬁeld may be lower.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
CCPP is not present (not detected) in the EU and not included in the list of notiﬁable diseases of
sheep and goats (Figure 1).
The latest outbreaks were reported in Saudi Arabia. In that case, however, it reﬂects more a recent
interest in reporting CCPP rather than a new introduction as the Middle East has been considered
infected for a very long time. These data combine all the epidemiological information which has been
available since the identiﬁcation of Mccp in 1976. Once established in a country, CCPP is supposed to
become endemic (in spite of the absence of subsequent ofﬁcial declarations) because of the lack of
efﬁcient control/eradication strategies.
The letters refer to the genotypes as stated in Dupuy et al. (2015).
Figure 1: CCPP distribution as reported to the World Organization for Animal Health (OIE) (adapted
from Peyraud et al., 2014)–
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Risk of introduction
Parameter 3 – Routes of possible introduction
CCPP is present in the Thrace region of Turkey, which borders Bulgaria and Greece.
CCPP may enter into the EU and remain hidden due to the inability to isolate Mccp by ‘most
standard labs’ and the use of antibiotics to treat infectious diseases (CCPP being confused with any
other mycoplasmosis that may induce similar lesions (Thiaucourt and B€olske, 1996)).
Wildlife may represent an additional risk (importation or exchanges by zoos).
Parameter 4 – Number of animal moving and/or shipment size
Importation of animals susceptible to CCPP from Turkey to the EU is prohibited on the basis of
Council Directive 2004/68/EC,1 establishing the general animal health conditions for the import into the
Union of ovine and caprine, and in Commission Regulation (EU) 206/20102, providing the list of the
non-EU countries authorised for the introduction into the EU of certain animal species. Undocumented
movements represent the main risk of introduction, and such movements are difﬁcult to trace although
it is known that they may occur (e.g. occasional undocumented trespassing from Turkish Thrace to
Greece or Bulgaria is not absolutely excluded, but both MSs take active measures to prevent such
illegal movement).
Parameter 5 – Duration of infectious period in animal and/or commodity
See Section 3.1.1.5.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
Ban of import from infected zones.
Parameter 7 – Presence and duration of latent infection and/or carrier status
As stated in Section 3.1.1.5, Parameter 3, there is no data on the duration of carrier status. There
is an historical example showing that this carrier stage may last for quite long as CCPP was introduced
into the Cape Colony in 1881 with a shipment of goats from Turkey. These animals had been moved
by boat. The trip lasted 7 weeks and no illness was evident in those goats until they were sold and
transmitted the disease to local goats (Hutcheon, 1881).
Parameter 8 – Risk of introduction
Entry of contaminated goats into the EU
This risk is considered ‘as likely as not’.
The most obvious risk for introduction of CCPP into the EU lies at the borders with Turkey, as CCPP
was reported in the Thrace region (Ozdemir et al., 2005). However, CCPP has also been reported in
the eastern part of Turkey (Cetinkaya et al., 2009). Therefore, it is probable that CCPP also circulates
in Armenia and Georgia, which have common borders with Russia. There is then a risk that CCPP
distribution could extend to southern Russia.
In 2005, the borders between Turkey and Bulgaria or Greece were certainly not as tight as they are
now because of the migrant crisis.
The only way to evaluate this risk would be to establish a serosurveillance programme in the
regions bordering Turkey:
• Use of the cELISA which is strictly speciﬁc: random selection of herds and targeted selection of
animals in the herds (those that are older or showed respiratory signs in the past two years) to
increase sensitivity while maintaining speciﬁcity at the herd level.
• Awareness campaign for goat herd owners, technicians and vets in the same region to ensure
proper reporting of suspicious cases.
1 Council Directive 2004/68/EC of 26 April 2004 laying down animal health rules for the importation into and transit through the
Community of certain live ungulate animals, amending Directives 90/426/EEC and 92/65/EEC and repealing Directive 72/462/EEC.
OJ L 139, 30.4.2004, p. 321–360.
2 Commission Regulation (EU) No 206/2010 of 12 March 2010 laying down lists of third countries, territories or parts thereof
authorised for the introduction into the European Union of certain animals and fresh meat and the veterinary certiﬁcation
requirements. OJ L 73, 20.3.2010, p. 1–121.
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The risk linked to uncontrolled movement of goats from the Maghreb region into the EU is not
considered very likely because, if that occurred, PPR, which is present in that region, would have been
detected.
Importing wildlife for zoos from infected zones (Asia, Africa; Middle East, etc.) should be
followed with great care
This risk is considered very unlikely, as these animals are seldom in contact with infected goats and
that distance transmission of CCPP is not frequent.
The risk could be mitigated by performing a serological test either at the individual level or better
at the herd level at the origin of import. The cELISA is not ofﬁcially validated for species other than
goats but as it is based on a competition, it can detect antibodies in infected animals other than goats.
It has been used successfully in sand gazelles.
If wild/zoo animals have been properly vaccinated, they should become serologically positive,
provided that a correct vaccine has been used.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Direct detection of Mccp
• Isolation of Mccp is very difﬁcult due to the fastidiousness of this mycoplasma. Isolation
requires very rich media which are not in routine use. Colonies are very small, especially upon
primary isolation, and require stereomicroscopes for observations. Consequently, labs which
perform routine diagnostic procedures are not able to isolate Mccp.
Speciﬁc PCR and quantitative PCR (Q-PCR): A speciﬁc PCR was developed in 2004 (Woubit et al.,
2004). Another PCR was developed earlier, but it required a digestion of the ampliﬁed product to
achieve identiﬁcation (Bascunana et al., 1994).
A Q-PCR was then developed based on the same primers (Lorenzon et al., 2008). However,
sensitivity is not an issue when acute CCPP cases are found, as the mycoplasma concentration is huge
in the pleural ﬂuid.
A multiplex PCR was developed to detect Mccp as well as other goat pathogens (Settypalli et al., 2016).
• Fine differentiation of strains can be achieved by an extended multilocus sequence analysis
(MLSA) technique. This technique allowed the identiﬁcation of six clades within Mccp strains
(now seven with an additional strain from China) (Dupuy et al., 2015).
Assembling full Mccp genomes is quite easy due to the good conservation of genome organisation.
Indirect detection
The complement ﬁxation test (CFT) should not be used for CCPP as there are many cross reactions
within the M. mycoides cluster species, or closely related species, that can be found in goats (M. capricolum
subsp. capricolum, M. mycoides subsp. capri, M. leachii, M. putrefaciens, M. ferriruminatoris, etc.).
There is an agglutination test based on latex beads sensitised with polysaccharides (CapriLAT, APHA
diagnostics). This test can be used to detect ongoing or recent outbreaks as it detects mostly IgMs.
However, Mccp shares the same polysaccharide at its surface with M. capricolum subsp. capricolum
and also M. leachii. There are therefore risks of false positive reactions.
There is now a speciﬁc cELISA test developed and validated at CIRAD (Validation dossier accepted
by the French Committee of Accreditation for CIRAD to be accredited ISO 17025 for this technique)
(Thiaucourt et al., 1994). This technique was used to evaluate the prevalence of CCPP in countries like
Kenya, Ethiopia, Mauritius, Tajikistan or Pakistan (Peyraud et al., 2014). This test can also be used to
verify the seroconversion in vaccinated animals. This test is marketed by IDEXX: Part Number:
99-56231.
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Control tools
Parameter 2 – Existence of control tools
There are basically four main control measures for CCPP: slaughter, control of movement, antibiotic
treatments and vaccination.
A strategy for the control/eradication of CCPP will inevitably be a combination of these control
measures that must be applied either at individual or at herd level and in a timely spatiotemporal way.
Slaughter and control of animal movement will not be discussed, as these are not speciﬁc for CCPP.
Antibiotic treatments
Although antibiotic treatments are banned when CCPP is diagnosed, there is a signiﬁcant chance
that these treatments are administered by veterinarians when respiratory signs are detected in goat
herds, and before any deﬁnitive diagnostic result is obtained. There are also signiﬁcant chances that
CCPP signs will be confused with other Mycoplasma infections.
These antibiotic treatments may be quite effective, and they will lead to a lack of detection and
possible unnoticed expansion of the disease unless some speciﬁc lesions are discovered (and
conﬁrmed as CCPP) after slaughter. Unfortunately, necropsies are not regularly performed on dead
goats.
Mycoplasma infections are usually treated with macrolide, lincosamide, streptogramins, ﬂuoroquinones
and tetracyclines. Currently, Mccp strains are susceptible to these classes of antibiotics and so far
only strains resistant to erythromycin have been detected. However, due to a higher mutation rate,
Mccp strains are likely to become resistant to these antibiotics by modiﬁcation of the antibiotic
targets.
Vaccines
Inactivated and saponin adjuvanted vaccines were developed (Rurangirwa et al., 1981, 1984,
1987a,b), and they proved efﬁcient in the ﬁeld (Litamoi et al., 1989).
Their main drawback is their cost due to the difﬁculties in Mccp growth, requiring rich medium and
quite large doses of puriﬁed antigen (0.15 mg) to induce a correct protection. There are few CCPP
vaccine producers in Africa (NVI Ethiopia, KEVEVAPI, Kenya) and in the Middle East (JOVAC Jordan,
IBRIZE Saudi Arabia, VETAL Turkey) or in China.
Previous experience at CIRAD has shown that some doubts could be raised on the proper quality of
these vaccines, especially in relation to the requirements of the European Pharmacopoeia (Thiaucourt,
2017).
There is a need for the development of more efﬁcient and cheaper vaccines for CCPP.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
None.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Precise data are not available.
In the case of an epizootic situation, the cumulative mortality can reach 70% when there is no
antibiotic treatment in place. This has been observed in goats (Thiaucourt, 2017) in Ethiopia, in 1991.
However, in case of introduction into the EU, it can be expected that infected goats would be
treated with antibiotics, and this would reduce the losses. In any case, it is expected that treated
goats may not recover completely because of the lung lesions and adherent scar tissue.
Pregnant goats may abort (due to high fever). Milk production can be reduced not because of
mastitis but simply because of fever and general dullness. However, no quantitative estimates are
available in the bibliography.
Usually, goats are raised mostly for milk; hence, there is no important impact on meat production.
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3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not applicable as CCPP is not zoonotic.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
CCPP is very painful because of the severity of the pleuropneumonia lesions lasting maximally
10 days for the acute form. Recovered animals also suffer because of ﬁbrous scar tissues adhering
between the lungs and the pleura.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
It is suspected that all wild ruminant species can be affected by CCPP.
Parameter 2 – Mortality in wild species
The mortality in wild species can be very high; levels up to 70% are recorded in sand gazelles in
the United Arab Emirates.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
There is no persistence in the environment.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
CCPP is listed in the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2017 (OIE,
2017), but not in the CFSPH for potential bioterrorism and agroterrorism agents.
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
Although CCPP is listed in the list of human and animal pathogens and toxins for export control from
the Australia Group, it is not listed in the Encyclopaedia of Bioterrorism Defense of Australia Group.
Parameter 3 – Included in any other list of potential bio-agroterrorism agents
It is not listed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Complement ﬁxation test, latex agglutination and cELISA are not yet recognised as OIE certiﬁed
tests. CFT should be abandoned as it is not speciﬁc.
The cELISA is now produced by IDEXX (Part Number: 99-56231) and all batches are quality
assured by CIRAD before release.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
The cut-off of the cELISA has been set at 55 PI to obtain a very high speciﬁcity (99.9%) when
performed under quality assurance.
This high speciﬁcity is detrimental to individual sensitivity. The test is, therefore, conceived as a
herd test.
In any case, herds are considered the most appropriate epidemiological unit to control CCPP.
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Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
Serum.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
Inactivated adjuvant vaccines (0.15 mg Mycoplasma antigen and 3 mg saponin).
Parameter 2 – Availability/production capacity (per year)
Very limited so far. Ethiopia and Kenya are even not meeting their own internal needs (about 2
million doses produced yearly). Other producers in the Middle East may soon put some products on
the market (JOVAC in Jordan, IBRIZE in Saudi Arabia).
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
Very limited data are available. There is a very good protection when the vaccine is produced
correctly (Rurangirwa et al., 1987a,b).
Parameter 4 – Duration of protection
The duration of protection is at least one year.
Feasibility
Parameter 5 – Way of administration
It is administered subcutaneously. The presence of saponin may induce a transient local reaction
and dullness in vaccinated animals for 24 h.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
Mccp is susceptible to classes of antibiotics used to treat Mycoplasma infections, e.g. macrolides,
lincosamide, streptogramins, ﬂuoroquinones and tetracyclines. However, no treatment is applied.
Parameter 2 – Availability/production capacity (per year)
These classes of antibiotics are available commercially without any shortage problem.
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
Antibiotics are able to cure the symptoms if they appear sufﬁciently rapidly. The problem with goats
is that they very often do not show overt signs of disease until the lesions are quite extensive. In that
case, it may be advisable to treat the entire ﬂock when CCPP is identiﬁed.
Feasibility
Parameter 4 – Way of administration
It depends on the type of antibiotic.
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3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
Quarantine is not to be considered, as the exact duration of carrier state for CCPP is not known.
Long quarantine periods neither would be economically feasible nor would they ensure that the
animals are not Mccp carriers at the end of the quarantine period.
In an outbreak, once animals have been slaughtered, disinfection will ensure that Mccp will
effectively and very rapidly be destroyed. Classical disinfectants are active on mycoplasmas (e.g.
bleach, detergents).
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Quarantine is not considered an effective measure to prevent CCPP introduction. Disinfection of
premises and operators boots will effectively prevent the spread of Mccp. In any case, the risk lies in
the presence of Mccp-contaminated droplets being transported at a distance which could infect other
herds in the vicinity. It is, therefore, important to consider avoiding devices which may generate such
aerosols (high pressure devices).
Feasibility
Parameter 3 – Feasibility of biosecurity measures
Spraying disinfectants and preparing disinfectant baths at the entry of the facilities can be easily
implemented.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
CCPP being spread by direct contact, the restriction of movement will be effective. The difﬁculty will
be to determine the zone that is considered infected.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between-farm spread
Prohibiting the import of goats from infected zones or countries is the only way to prevent CCPP
introduction. This measure can be effective unless wind transport of infected droplets may lead to
distant contaminations between farms. This distance has been proven to be at least 80 m, but longer
distances have to be taken for granted if a parallel is made with CBPP or other Mycoplasma diseases,
for which distances up to at least 9 km have been reported (Otake et al., 2010). Nevertheless, given
the very low resistance of Mccp in the environment, the probability of occurrence of such high distance
transmission by wind currents is very unlikely.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
Restriction of goat movements in case of CCPP outbreaks will be feasible only if CCPP is included in
the list of notiﬁable diseases in all Member States. This inclusion could assist into implement the local
regulations prohibiting movements and deploying the forces that are able to ensure the effectivity of
the measures.
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
Again, because CCPP is transmitted by live animals shedding Mycoplasma-contaminated droplets,
slaughter is the ultimate means to cut the epidemiological cycle.
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This killing has to be considered at the herd level for faster and greater efﬁciency (and also
because vaccines are neither readily available in the EU nor authorised).
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing /stopping
spread of the disease
This is highly effective and certainly the most efﬁcient way to eradicate CCPP.
However, it must be noted that this strategy would be efﬁcient in eradicating CCPP only if applied
to all herds in the infected zone.
Feasibility
Parameter 3 – Feasibility of killing animals
Killing animals is easy to perform from a technical point of view. Humane slaughter of affected
herds can be implemented as there is no zoonotic risk and very limited risk of distance transmission
from infected droplets. Slaughter areas can be disinfected afterward with classical disinfectants.
Mycoplasmas do not have a cell wall and will be rapidly inactivated.
However, some reluctance is to be expected from the goat owners, especially if the culling strategy
has to be applied on a large scale.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
CCPP is not zoonotic, and Mccp does not persist in the environment. Therefore, there are no
speciﬁc measures for the disposal of carcasses.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
As for CBPP, this cost is impossible to predict. The example of Mycoplasma bovis infection in the EU
has shown that treatments were not sufﬁcient to prevent the slow but unstoppable expansion of the
infection with examples in Switzerland and Austria (B€urki et al., 2016).
Although no ofﬁcial control measures are foreseen in Europe, except slaughter, for CCPP a
combined strategy including the treatment of sick animals and vaccination of all others may lead to
eradication. However, this strategy has never been used experimentally in the ﬁeld.
Other costs
The cost of surveillance and monitoring will depend on the local situation.
In terms of trade loss, living goats will not be able to be exchanged as CCPP is an OIE notiﬁable
disease.
However, goat milk and cheese or meat are not considered as dangerous products; hence, the
economic impact of the ban on living animals movements may be limited.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Culling goats may prove to be difﬁcult as these animals are sometimes considered as pets.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
There are theoretically no welfare issue as humane slaughtering will be implemented.
Parameter 2 – Wildlife depopulation as control measure
There is no welfare issue so far as no European wildlife is considered susceptible to CCPP. In case
of outbreaks in zoo animals, humane slaughtering will be implemented.
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3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Antibiotic treatments for CCPP are likely to induce the emergence of resistant Mccp strains. This is
the reason why eradication through slaughter should be advocated.
Biodiversity
Parameter 2 – Mortality in wild species
Mortality may be very high in wild species (for example, 70% in sand gazelles). Therefore, CCPP
could be considered a potential risk for endangered species. In Tajikistan, CCPP has been suspected to
occur in markhors (Capra falconeri), which is considered now as ‘near threatened’ by the IUCN.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about CCPP (Table 1). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 1: Outcome of the expert judgement on the Article 5 criteria for contagious caprine
pleuropneumonia
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist
in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
NC
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
NC
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
AHL assessment on contagious caprine pleuropneumonia
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2017;15(10):4996
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 2–4). The proportion of Y, N or na answers are reported, followed
by the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting No:
• There are no studies of antimicrobial resistance for this speciﬁc pathogen reported.
• Antimicrobial resistance is quite common in other mycoplasma species, and also Mccp could
potentially develop it. However, there is no treatment allowed; therefore, the impact on animal
or public health is not signiﬁcant.
Supporting na:
• There is a lack of data.
Reasoning supporting the judgement
Supporting Yes:
• Even if the disease is not listed for bioterrorism, there are probably huge consequences on
intracommunity trade and EU exports for sheep and goats due to trade restriction.
• It is not listed; however, both the disease and any response would likely generate a crisis in
the period after introduction.
Supporting No:
• It is not listed as potential agent for bioterrorism and unlikely to generate a crisis.
Reasoning supporting the judgement
Supporting No:
• There is no evidence of signiﬁcant effect on wild ruminants/European wildlife. The disease
would only affect populations that are not endangered.
Table 2: Outcome of the expert judgement related to criterion 5 B(ii)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(ii) The disease agent has developed resistance to treatments and
poses a signiﬁcant danger to public and/or animal health in the
Union
NC 0 42 58
NC: non-consensus; number of judges: 12.
Table 3: Outcome of the expert judgement related to criterion 5 B(iv)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(iv) The disease has the potential to generate a crisis or the
disease agent could be used for the purpose of bioterrorism
NC 33 67 0
NC: non-consensus; number of judges: 12.
Table 4: Outcome of the expert judgement related to criterion 5 B(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(v) The disease has or could have a signiﬁcant negative impact
on the environment, including biodiversity, of the Union
NC 0 8 92
NC: non-consensus; number of judges: 12.
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Supporting na:
• There is not enough information, it is not known how many species have been challenged and
not been affected (of concern in wild ruminants in other regions).
3.2.2. Outcome of the assessment of contagious caprine pleuropneumonia
according to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 1, CCPP
complies with all criteria of the ﬁrst set and with two criteria of the second set; therefore, it is
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about CCPP (Tables 5–9). The expert judgement was based on
ICBA approach described in detail in the opinion on the methodology. Experts have been provided with
information of the disease fact sheet mapped into Article 9 criteria (see supporting information, Annex A),
based on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9, and the
reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 5: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for contagious caprine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union or present only in exceptional cases
(irregular introductions) or present only in a very limited part of the territory of the Union
Y
2.1 The disease is highly transmissible NC
2.2 There are possibilities of airborne or waterborne or vector-borne spread NC
2.3 The disease affects multiple species of kept and wild animals or single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential or possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease or due to the measures taken to control it
NC
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term damage
to those species or breeds
NC
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
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Table 6: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for contagious caprine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole or part of the Union territory with an endemic character,
and (at the same time) several Member States or zones of the Union are free of the disease
N
2.1 The disease is moderately to highly transmissible NC
2.2 There are possibilities of airborne or waterborne or vector-borne spread NC
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential or possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease or due to the measures taken to control it
NC
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term damage
to those species or breeds
NC
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 7: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for contagious caprine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole or part of the Union territory with an endemic character N
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND
often the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health or
possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease or due to the measures taken to control it
NC
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 10–13).
The proportion of Y, N or `na0 answers is reported, followed by the list of different supporting views
for each answer.
Reasoning supporting the judgement
Supporting Yes for 2.1 (cat. A):
• The disease is very readily contagious, and only brief periods of contact are necessary for
successful transmission (Nicholas and Churchward, 2012).
• There is limited data, but an R0 of 2.5 for gazelles is reported, and the morbidity and
prevalence in outbreaks suggest high transmissibility.
Supporting Yes for 2.1 (cat. B, C):
• Transmissibility seems variable since various morbidity rates have been reported, depending in
particular on the altitude.
• R0 has been established at around 2.5 for gazelles, in an environment that was very favourable
to transmission (high densities of animals held in pens) (Lignereux et al., 2017). Hence, the
value for goats in the ﬁeld may be lower.
Supporting na for 2.1 (cat. A, B, C):
• No published data exist.
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term damage
to those species or breeds
NC
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 8: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for contagious caprine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
the disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 9: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for contagious caprine pleuropneumonia
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL and/
or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment
(If a disease fulﬁls the criteria as in Article 5, thus being eligible to be listed, consequently
category E would apply.)
Y
Colour code: green = consensus (Yes/No).
Table 10: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.1 (cat. A) The disease is highly transmissible NC 25 67 8
2.1 (cat. B, C) The disease is moderately to highly transmissible NC 67 25
NC: non-consensus; number of judges: 12.
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Reasoning supporting the judgement
Supporting Yes:
• Airborne transmission is suspected to occur, but there is no biological vector-borne
transmission.
Supporting No:
• No evidence of indirect transmission has been shown as the mycoplasma is highly fragile in the
environment (Nicholas and Churchward, 2012).
Supporting na:
• The fact sheet states that airborne spread is possible, but there are no references to support
this.
Reasoning supporting the judgement
Supporting No:
• There is no evidence of signiﬁcant effect on wild ruminants/European wildlife. The disease
would only affect populations that are not endangered.
Supporting na:
• It is suspected that all wild ruminant species can be affected. Mortality in wild species can be
very high. However, there are very few endangered ruminants in the EU and no information of
EU wild endangered species that are susceptible.
Reasoning supporting the judgement
Please see reasoning for Table 12.
Table 11: Outcome of the expert judgement related to criterion 2.2 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.2 (cat. A, B) There are possibilities of airborne or waterborne or
vector-borne spread
NC 75 8 17
NC: non-consensus; number of judges: 12.
Table 12: Outcome of the expert judgement related to criterion 5(c) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(c) The disease has a signiﬁcant impact on the environment, due to the
direct impact of the disease or due to the measures taken to control it
NC 0 17 83
NC: non-consensus; number of judges: 12.
Table 13: Outcome of the expert judgement related to criterion 5(d) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(d) The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to
those species or breeds*
NC 0 17 83
NC: non-consensus; number of judges: 12.
*Endangered breeds are not considered.
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3.3.2. Outcome of the assessment of criteria in Annex IV for contagious caprine
pleuropneumonia for the purpose of categorisation as in Article 9 of the
AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 5–9. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for CCPP for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 14.
According to the assessment performed here, CCPP complies with the following criteria of the
Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a)–(e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment, CCPP complies with criteria 1, 2.3 and 2.4,
and the assessment is inconclusive on compliance with criteria 2.1 and 2.2. To be eligible for
category A, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and CCPP complies with criteria 4 and 5b but not with criteria 3 and 5a, and the
assessment is inconclusive on compliance with criteria 5c and 5d.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment, CCPP complies with criterion 2.3 but not with
criteria 1 and 2.4, and the assessment is inconclusive on compliance with criteria 2.1 and
2.2. To be eligible for category B, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d) and CCPP complies with criteria 4 and 5b but not with
criteria 3 and 5a, and the assessment is inconclusive on compliance with criteria 5c and 5d.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment, CCPP complies with criteria 2.2 and 2.3, but
not with criteria 1 and 2.4, and the assessment is inconclusive on compliance with criterion
2.1. To be eligible for category C, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d), and CCPP complies with criterion 5b, but not with
criteria 3, 4 and 5a, and the assessment is inconclusive on compliance with criteria 5c and 5d.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which CCPP
complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating to
Table 14: Outcome of the assessment of criteria in Annex IV for contagious caprine
pleuropneumonia for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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animal health, animal welfare, human health, the economy, society or the environment. The
latter is applicable if a disease fulﬁls the criteria as in Article 5, with which CCPP complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
CCPP. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.3 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for CCPP according to the criteria of
Article 8(3) of the AHL are as displayed in Table 15.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, CCPP complies with all criteria of the ﬁrst set
and with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, CCPP meets the criteria as in Sections 4 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (d) and (e) of Article 9(1) of the AHL. According to the assessment here performed, it
is inconclusive whether CCPP complies with the criteria as in Section 1 of Annex IV of the AHL,
for the application of the disease prevention and control rules referred to in point (a) of Article
9(1) of the AHL. Compliance of CCPP with the criteria as in Section 1 is dependent on a
decision on criteria 2.1 and 2.2.
Table 15: Main animal species to be listed for contagious caprine pleuropneumonia according to
criteria of Article 8 (source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Bovidae Goat (Capra hircus), wild goat (Capra aegagrus), Nubian
ibex (Capra ibex nubiana), Laristan mouﬂon (Ovis orientalis
laristanica), gerenuk (Litocranius walleri), Tibetan antelope
(Pantholops hodgsonii), Arabian oryx (Oryx leucoryx), Sand
gazelles (Gazella marica)
Reservoir Not identiﬁed*
Vectors None
*: Sheep may play the role of domestic reservoirs, although there is no clear evidence on this.
3 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for CCPP according to Article 8(3) of the AHL are goats and other species of the family
Bovidae as susceptible, as reported in Table 15 in Section 3.4 of the present document.
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AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
CBPP contagious bovine pleuropneumonia
CCPP Contagious caprine pleuropneumonia
cELISA competitive enzyme-linked immunosorbent assay
ICBA Individual and Collective Behavioural Aggregation
IUCN International Union for Conservation of Nature
AHL assessment on contagious caprine pleuropneumonia
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2017;15(10):4996
Mccp Mycoplasma capricolum subsp. capripneumoniae
MLSA multilocus sequence analysis
Mmm Mycoplasma mycoides subsp. mycoides
OIE World Organization for Animal Health
PCR polymerase chain reaction
PPR peste des petits ruminants
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Annex A – Mapped fact-sheet used in the individual judgement on
contagious caprine pleuropneumonia
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2017.4996
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